½ÃÀ庸°í¼­
»óǰÄÚµå
1402077

¼¼°èÀÇ ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2023-2030³â)

Global Medical Inhaled Nitric Oxide Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 184 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â-2030³â°£ 8.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î Áõ°¡ÇÏ¿© 2022³â 9¾ï 8,556¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â ¾à 18¾ï 9,287¸¸ ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò(iNO)´Â ´Ù¾çÇÑ È£Èí±â Áúȯ, ƯÈ÷ Æó°íÇ÷¾Ð°ú Àú»ê¼ÒÇ÷Áõ(Àú»ê¼ÒÇ÷Áõ) Ä¡·á¿¡ »ç¿ëµÇ´Â °¡½º ¾àǰÀÔ´Ï´Ù. »ê¼ÒÈ­¸¦ °³¼±ÇÏ°í ÆóÇ÷°ü ÁúȯÀ» °ü¸®Çϱâ À§ÇÑ Ä¡·áÀû °³ÀÔÀ¸·Î ÈíÀÔÀ» ÅëÇØ Åõ¿©µË´Ï´Ù.

½ÃÀå ¿ªÇÐ

±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ARDS)°ú Æó°íÇ÷¾ÐÀ» Æ÷ÇÔÇÑ È£Èí±â ÁúȯÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ÁúȯÀ» °ü¸®ÇÏ°í »ê¼Ò¸¦ °ø±ÞÇϱâ À§ÇØ ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò(iNO)¿Í °°Àº Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½Å»ý¾Æ ÀÇ·á¿¡¼­ iNO´Â ½Å»ý¾Æ Áö¼Ó¼º Æó°íÇ÷¾Ð Ä¡·á¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¹Ì¼÷¾Æ °Ç°­¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í ½Å»ý¾Æ ÀÇ·áÀÇ ¹ßÀü°ú ¸Â¹°·Á ÀÖ½À´Ï´Ù. ÀÇ·á ±â¼úÀÇ ¹ßÀü, Àü´Þ ½Ã½ºÅÛ ¹× ¸ð´ÏÅ͸µ µµ±¸ÀÇ °³¼±Àº iNO Ä¡·áÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» Çâ»ó½ÃÄÑ ÀÓ»ó ÇöÀå¿¡¼­ÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÆóÇ÷°ü Áúȯ °ü¸®¿Í »ê¼ÒÈ­ °³¼±¿¡ ´ëÇÑ iNOÀÇ ÀÓ»óÀû È¿´ÉÀÌ ÀÔÁõµÇ¸é¼­ ÀÇ·á Àü¹®°¡µé »çÀÌ¿¡¼­ iNO°¡ ÀÎÁ¤¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î È£Èí±â Áúȯ Ä¡·á¿¡ ´ëÇÑ iNOÀÇ ÀáÀç·ÂÀ» ޱ¸ÇÏ´Â ¿¬±¸°¡ ÁøÇà ÁßÀ̸ç, ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú ÀÇ·áºñ ÁöÃâ Áõ°¡·Î ÀÎÇØ ½ÃÀå È®´ë°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

ÀÌ Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ¼¼°è ÀÇ·á¿ë ÈíÀÔ Áú¼Ò »êÈ­¹° ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÇ·á¿ë ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ÀÀ¿ë ºÐ¾ß¿¡ ´ëÇÑ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

¸ÂÃãÇü ¿ä±¸»çÇ×ÀÌ ÀÖ´Â °æ¿ì, ´ç»ç·Î ¿¬¶ô ºÎʵ右´Ï´Ù. ´ç»çÀÇ Á¶»ç ÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò - »ê¾÷ ºÐ¼®

  • ¼­·Ð - ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • PorterÀÇ Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·á °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò ½ÃÀå ºÐ¼® : Á¦Ç° À¯Çüº°

  • °³¿ä : Á¦Ç° À¯Çüº°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ºÐ¼® : Á¦Ç° À¯Çüº°
  • ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò Àü´Þ ½Ã½ºÅÛ
  • ÀÏ»êÈ­Áú¼Ò ¼¾¼­ ¹× ¸ð´ÏÅÍ

Á¦6Àå ¼¼°èÀÇ ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò ½ÃÀå ºÐ¼® : Åõ¿© °æ·Îº°

  • Åõ¿© °æ·Îº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Åõ¿© °æ·Îº° ºÐ¼®
  • ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò °¡½º
  • »ê¼Ò È¥ÇÕ ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò

Á¦7Àå ¼¼°èÀÇ ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò ½ÃÀå ºÐ¼® : ¿ëµµº°

  • °³¿ä : ¿ëµµº°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ºÐ¼® : ¿ëµµº°
  • ½ÉÇ÷°üÁúȯ
  • È£Èí±âÁúȯ

Á¦8Àå ¼¼°èÀÇ ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾»ç¿ëÀÚº° ºÐ¼®
  • º´¿ø
  • Áø·á¼Ò

Á¦9Àå ¼¼°èÀÇ ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ÆÇ¸Å ºÐ¼®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò ±â¾÷ °æÀï ±¸µµ

  • ÀÇ·á¿ë ÈíÀÔ¿ë ÀÏ»êÈ­Áú¼Ò ½ÃÀå °æÀï
  • Á¦ÈÞ/Çù·Â/ÇÕÀÇ
  • ÀμöÇÕº´(M&A)
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦11Àå ±â¾÷ °³¿ä

  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Bellerophon Therapeutics
  • Praxair Technology Inc.(Linde plc)
  • Mallinckrodt Pharmaceuticals
  • GE Healthcare
  • Mitsubishi Tanabe Pharma Corporation
  • Vero Biotech LLC
  • Messer Group
  • Air Liquide
  • Nu-Med Plus
  • Beyond Air Inc.
LSH 24.01.09

The global demand for Medical Inhaled Nitric Oxide Market is presumed to reach the market size of nearly USD 1892.87 MN by 2030 from USD 985.56 MN in 2022 with a CAGR of 8.5% under the study period 2023 - 2030.

Medical inhaled nitric oxide (iNO) is a gas medication used in the treatment of various respiratory conditions, particularly those involving pulmonary hypertension or hypoxemia (low blood oxygen levels). It is delivered through inhalation as a therapeutic intervention to improve oxygenation and manage pulmonary vascular disorders.

MARKET DYNAMICS

The increasing incidence of respiratory disorders, including acute respiratory distress syndrome (ARDS) and pulmonary hypertension, propels the demand for therapies like inhaled nitric oxide (iNO) to manage these conditions and enhance oxygenation. Within neonatal care, iNO plays a critical role in treating persistent pulmonary hypertension in neonates, aligning with the heightened focus on preterm infant health and advancements in neonatal care practices. Advancements in healthcare technology, improved delivery systems, and monitoring tools enhance the safety and efficacy of iNO therapy, augmenting its adoption in clinical settings. The proven clinical effectiveness of iNO in managing pulmonary vascular disorders and improving oxygenation fosters its acceptance among healthcare professionals. Moreover, ongoing research exploring iNO's potential in treating additional respiratory conditions, alongside regulatory support and increased healthcare spending, collectively drive market expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of medical inhaled nitric oxide. The growth and trends of medical inhaled nitric oxide industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the medical inhaled nitric oxide market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

  • Inhaled Nitric Oxide Delivery Systems
  • Nitric Oxide Sensors And Monitors

By Route Of Administration

  • Inhaled Nitric Oxide Gas
  • Inhaled Nitric Oxide With Oxygen Mixtures

By Application

  • Cardiovascular Disorders
  • Respiratory Disorders

By End User

  • Hospitals
  • Clinics

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Medical Inhaled Nitric Oxide market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Medical Inhaled Nitric Oxide market include Bellerophon Therapeutics, Praxair Technology Inc. (Linde plc), Mallinckrodt Pharmaceuticals, GE Healthcare, Mitsubishi Tanabe Pharma Corporation, Vero Biotech LLC, Messer Group, Air Liquide, Nu-Med Plus, Beyond Air Inc., and others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . MEDICAL INHALED NITRIC OXIDE - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product Type
    • 3.7.2 Market Attractiveness Analysis By Route of Administration
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By End User
    • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL MEDICAL INHALED NITRIC OXIDE MARKET ANALYSIS BY PRODUCT TYPE

  • 5.1 Overview by Product Type
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Product Type
  • 5.4 Inhaled Nitric Oxide Delivery Systems Historic and Forecast Sales by Regions
  • 5.5 Nitric Oxide Sensors and Monitors Historic and Forecast Sales by Regions

6 . GLOBAL MEDICAL INHALED NITRIC OXIDE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1 Overview by Route of Administration
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Route of Administration
  • 6.4 Inhaled Nitric Oxide Gas Historic and Forecast Sales by Regions
  • 6.5 Inhaled Nitric Oxide with Oxygen Mixtures Historic and Forecast Sales by Regions

7 . GLOBAL MEDICAL INHALED NITRIC OXIDE MARKET ANALYSIS BY APPLICATION

  • 7.1 Overview by Application
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Application
  • 7.4 Cardiovascular Disorders Historic and Forecast Sales by Regions
  • 7.5 Respiratory Disorders Historic and Forecast Sales by Regions

8 . GLOBAL MEDICAL INHALED NITRIC OXIDE MARKET ANALYSIS BY END USER

  • 8.1 Overview by End User
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End User
  • 8.4 Hospitals Historic and Forecast Sales by Regions
  • 8.5 Clinics Historic and Forecast Sales by Regions

9 . GLOBAL MEDICAL INHALED NITRIC OXIDE MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. South East Asia Sales Analysis
    • 9.5.10. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE MEDICAL INHALED NITRIC OXIDE COMPANIES

  • 10.1. Medical Inhaled Nitric Oxide Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF MEDICAL INHALED NITRIC OXIDE INDUSTRY

  • 11.1. Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Bellerophon Therapeutics
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Praxair Technology Inc. (Linde plc)
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Mallinckrodt Pharmaceuticals
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. GE Healthcare
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Mitsubishi Tanabe Pharma Corporation
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. Vero Biotech LLC
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Messer Group
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Air Liquide
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Nu-Med Plus
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Beyond Air Inc.
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Others
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦